USA - NASDAQ:SIEN - US82621J2042 - Common Stock
The current stock price of SIEN is 0.174 USD. In the past month the price decreased by -69.47%. In the past year, price decreased by -89.45%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 24.59 | 37.11B | ||
| COO | COOPER COS INC/THE | 17.16 | 13.72B | ||
| SOLV | SOLVENTUM CORP | 10.9 | 11.49B | ||
| ALGN | ALIGN TECHNOLOGY INC | 13.83 | 9.69B | ||
| BLCO | BAUSCH + LOMB CORP | 36.12 | 5.50B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.26 | 5.12B | ||
| LNTH | LANTHEUS HOLDINGS INC | 8.4 | 3.65B | ||
| ICUI | ICU MEDICAL INC | 17.24 | 3.20B | ||
| XRAY | DENTSPLY SIRONA INC | 6.44 | 2.20B | ||
| HAE | HAEMONETICS CORP/MASS | 14.43 | 3.23B | ||
| UFPT | UFP TECHNOLOGIES INC | 25 | 1.72B | ||
| ESTA | ESTABLISHMENT LABS HOLDINGS | N/A | 1.88B |
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. The company is headquartered in Irvine, California and currently employs 304 full-time employees. The company went IPO on 2014-10-29. The firm is engaged in transformative treatments and technologies focused on advancing plastic surgery. The firm provides medical aesthetics products to certified plastic surgeons and patients. The company has developed a portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The firm sells its breast implants, breast tissue expanders, and fat transfer system for reconstruction procedures predominantly to hospitals and surgery centers, and its BIOCORNEUM scar management products to plastic surgeons, dermatologists and other specialties. The firm's brands also include Sientra, Sientra Platinum20, Sientra Full Circle, Sientra Smooth, Sientra Teardrop, AlloX, AlloX2, Anatomical Controlled, BIOCORNEUM, Curve, Dermaspan, Luxe, Softspan, Silishield, AuraClens and Viality.
SIENTRA INC
3333 Michaelson Dr, Suite 650
Irvine CALIFORNIA 93117 US
CEO: Ronald Menezes
Employees: 304
Phone: 18055623500
Sientra, Inc. operates as a medical aesthetics company, which engages in developing and commercializing plastic surgery implantable devices. The company is headquartered in Irvine, California and currently employs 304 full-time employees. The company went IPO on 2014-10-29. The firm is engaged in transformative treatments and technologies focused on advancing plastic surgery. The firm provides medical aesthetics products to certified plastic surgeons and patients. The company has developed a portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The firm sells its breast implants, breast tissue expanders, and fat transfer system for reconstruction procedures predominantly to hospitals and surgery centers, and its BIOCORNEUM scar management products to plastic surgeons, dermatologists and other specialties. The firm's brands also include Sientra, Sientra Platinum20, Sientra Full Circle, Sientra Smooth, Sientra Teardrop, AlloX, AlloX2, Anatomical Controlled, BIOCORNEUM, Curve, Dermaspan, Luxe, Softspan, Silishield, AuraClens and Viality.
The current stock price of SIEN is 0.174 USD. The price decreased by -18.69% in the last trading session.
SIEN does not pay a dividend.
SIEN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
SIENTRA INC (SIEN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.57).
SIENTRA INC (SIEN) has a market capitalization of 2.08M USD. This makes SIEN a Nano Cap stock.
ChartMill assigns a fundamental rating of 1 / 10 to SIEN. Both the profitability and financial health of SIEN have multiple concerns.
Over the last trailing twelve months SIEN reported a non-GAAP Earnings per Share(EPS) of -5.57. The EPS increased by 48.9% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.26% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
9 analysts have analysed SIEN and the average price target is 2.04 USD. This implies a price increase of 1072.41% is expected in the next year compared to the current price of 0.174.
For the next year, analysts expect an EPS growth of 61.42% and a revenue growth -3.12% for SIEN